{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:11:32Z","timestamp":1747195892573,"version":"3.40.5"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T00:00:00Z","timestamp":1604880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007579","name":"Auburn University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007579","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Gene therapy is a promising treatment option for cancer. However, its utility may be limited due to expression in off-target cells. Cancer-specific promoters such as telomerase reverse transcriptase (TERT), survivin, and chemokine receptor 4 (CXCR4) have enhanced activity in a variety of human and murine cancers, however, little has been published regarding these promoters in dogs. Given the utility of canine cancer models, the activity of these promoters along with adenoviral E2F enhanced E1a promoter (EEE) was evaluated in a variety of canine tumors, both from the endogenous gene and from exogenously administered constructs. Endogenous expression levels were measured for cTERT, cSurvivin, and cCXCR4 and were low for all three, with some non-malignant and some tumor cell lines and tissues expressing the gene. Expression levels from exogenously supplied promoters were measured by both the number of cells expressing the construct and the intensity of expression in individual cells. Exogenously supplied promoters were active in more cells in all tumor lines than in normal cells, with the EEE promoter being most active, followed by cTERT. The intensity of expression varied more with cell type than with specific promoters. Ultimately, no single promoter was identified that would result in reliable expression, regardless of the tumor type. Thus, these findings imply that identification of a pan-cancer promoter may be difficult. In addition, this data raises the concern that endogenous expression analysis may not accurately predict exogenous promoter activity.<\/jats:p>","DOI":"10.1371\/journal.pone.0240807","type":"journal-article","created":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T18:44:12Z","timestamp":1604947452000},"page":"e0240807","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-3147","authenticated-orcid":true,"given":"Abdul Mohin","family":"Sajib","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maninder","family":"Sandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Morici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-0355","authenticated-orcid":true,"given":"Bruce F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,11,9]]},"reference":[{"issue":"5110","key":"pone.0240807.ref001","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.8493530","article-title":"The Basic Science of Gene-Therapy","volume":"260","author":"RC Mulligan","year":"1993","journal-title":"Science"},{"issue":"2","key":"pone.0240807.ref002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nbt.1769","article-title":"Gene therapy finds its niche","volume":"29","author":"C Sheridan","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"3","key":"pone.0240807.ref003","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3121\/cmr.4.3.218","article-title":"Gene therapy for cancer treatment: past, present and future","volume":"4","author":"D Cross","year":"2006","journal-title":"Clin Med Res"},{"issue":"2","key":"pone.0240807.ref004","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1155\/S1110724303209074","article-title":"Transcriptional targeting in cancer gene therapy","author":"T Robson","year":"2003","journal-title":"J Biomed Biotechnol"},{"issue":"8","key":"pone.0240807.ref005","article-title":"Development of a cancer targeted tissue specific promoter system","volume":"66","author":"T Fukazawa","year":"2006","journal-title":"Cancer Res"},{"issue":"3","key":"pone.0240807.ref006","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1525-0016(02)00059-X","article-title":"Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer","volume":"7","author":"S Furuhata","year":"2003","journal-title":"Mol Ther"},{"issue":"17","key":"pone.0240807.ref007","first-page":"3860","article-title":"Use of Tissue-Specific Expression of the Herpes-Simplex Virus Thymidine Kinase Gene to Inhibit Growth of Established Murine Melanomas Following Direct Intratumoral Injection of DNA","volume":"53","author":"RG Vile","year":"1993","journal-title":"Cancer Res"},{"issue":"12","key":"pone.0240807.ref008","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1128\/MCB.11.12.5885","article-title":"A Position-Dependent Silencer Plays a Major Role in Repressing Alpha-Fetoprotein Expression in Human Hepatoma","volume":"11","author":"H Nakabayashi","year":"1991","journal-title":"Mol Cell Biol"},{"key":"pone.0240807.ref009","first-page":"7","article-title":"Hepatocellular carcinoma-targeting oncolytic adenovirus overcomes hypoxic tumor microenvironment and effectively disperses through both central and peripheral tumor regions","author":"AR Yoon","year":"2018","journal-title":"Sci Rep-Uk"},{"issue":"4","key":"pone.0240807.ref010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0168-9525(99)01950-2","article-title":"Gene therapy\u2014designer promoters for tumour targeting","volume":"16","author":"DM Nettelbeck","year":"2000","journal-title":"Trends Genet"},{"issue":"2","key":"pone.0240807.ref011","first-page":"100","article-title":"The role of survivin in diagnosis, prognosis and treatment of breast cancer","volume":"2","author":"YG Lv","year":"2010","journal-title":"J Thorac Dis"},{"issue":"3","key":"pone.0240807.ref012","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1245\/s10434-010-1371-y","article-title":"Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India","volume":"18","author":"R Upadhyay","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"pone.0240807.ref013","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.1999.17.7.2100","article-title":"A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers","volume":"17","author":"M Monzo","year":"1999","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0240807.ref014","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"G Ambrosini","year":"1997","journal-title":"Nat Med"},{"issue":"10","key":"pone.0240807.ref015","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.14202\/vetworld.2017.1286-1291","article-title":"Survivin expression in canine spontaneous cutaneous and subcutaneous tumors and its prognostic importance","volume":"10","author":"N Kavya","year":"2017","journal-title":"Vet World"},{"key":"pone.0240807.ref016","first-page":"16","article-title":"Survivin: a unique target for tumor therapy","author":"H Garg","year":"2016","journal-title":"Cancer Cell Int"},{"key":"pone.0240807.ref017","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0971-5916.159250","article-title":"Survivin: A molecular biomarker in cancer","volume":"141","author":"PK Jaiswal","year":"2015","journal-title":"Indian J Med Res"},{"issue":"9","key":"pone.0240807.ref018","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1084\/jem.190.9.1241","article-title":"Human G protein-coupled receptor GPR-9-6\/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis","volume":"190","author":"BA Zabel","year":"1999","journal-title":"J Exp Med"},{"issue":"6685","key":"pone.0240807.ref019","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development","volume":"393","author":"YR Zou","year":"1998","journal-title":"Nature"},{"key":"pone.0240807.ref020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1146\/annurev.pharmtox.48.121806.154841","article-title":"Chemokines and their receptors: Drug targets in immunity and inflammation","volume":"48","author":"A Viola","year":"2008","journal-title":"Annu Rev Pharmacol"},{"issue":"36","key":"pone.0240807.ref021","doi-asserted-by":"crossref","first-page":"23169","DOI":"10.1074\/jbc.273.36.23169","article-title":"The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways","volume":"273","author":"RK Ganju","year":"1998","journal-title":"J Biol Chem"},{"issue":"2","key":"pone.0240807.ref022","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020185","article-title":"Involvement of CXCR4 in Normal and Abnormal Development","volume":"8","author":"N Kawaguchi","year":"2019","journal-title":"Cells"},{"key":"pone.0240807.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The Intricate Role of CXCR4 in Cancer","volume":"124","author":"S Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"issue":"5","key":"pone.0240807.ref024","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"JA Burger","year":"2006","journal-title":"Blood"},{"issue":"1","key":"pone.0240807.ref025","first-page":"1","article-title":"Defining the molecular mechanisms of human cell immortalization","volume":"1072","author":"JW Shay","year":"1991","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"pone.0240807.ref026","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/8.1.137","article-title":"The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter","volume":"8","author":"YS Cong","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"9","key":"pone.0240807.ref027","article-title":"Telomerase Regulation from Beginning to the End","volume":"7","author":"DE MacNeil","year":"2016","journal-title":"Genes-Basel"},{"issue":"8","key":"pone.0240807.ref028","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00018-016-2146-9","article-title":"Reactivation of telomerase in cancer","volume":"73","author":"SC Akincilar","year":"2016","journal-title":"Cell Mol Life Sci"},{"issue":"35","key":"pone.0240807.ref029","doi-asserted-by":"crossref","first-page":"e11794","DOI":"10.1097\/MD.0000000000011794","article-title":"The prognostic significance of hTERT overexpression in cancers: A systematic review and meta-analysis","volume":"97","author":"K Wang","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"pone.0240807.ref030","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1182\/blood.V85.9.2315.bloodjournal8592315","article-title":"Telomerase Activity in Normal Leukocytes and in Hematologic Malignancies","volume":"85","author":"CM Counter","year":"1995","journal-title":"Blood"},{"issue":"1","key":"pone.0240807.ref031","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12929-018-0422-8","article-title":"Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer","volume":"25","author":"R Leao","year":"2018","journal-title":"J Biomed Sci"},{"key":"pone.0240807.ref032","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.2147\/DDDT.S49584","article-title":"Animal models and therapeutic molecular targets of cancer: utility and limitations","volume":"8","author":"M Cekanova","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"pone.0240807.ref033","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molmed.2011.02.004","article-title":"Dog models of naturally occurring cancer","volume":"17","author":"JL Rowell","year":"2011","journal-title":"Trends Mol Med"},{"key":"pone.0240807.ref034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tvjl.2018.08.008","article-title":"Companion animals in comparative oncology: One Medicine in action","volume":"240","author":"OA Garden","year":"2018","journal-title":"Vet J"},{"key":"pone.0240807.ref035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev-animal-022114-110911","article-title":"Dogs as a Model for Cancer","volume":"4","author":"HL Gardner","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"issue":"1","key":"pone.0240807.ref036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hon.2017","article-title":"The dog as a possible animal model for human non-Hodgkin lymphoma: a review","volume":"31","author":"L Marconato","year":"2013","journal-title":"Hematol Oncol"},{"issue":"1","key":"pone.0240807.ref037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1748-5827.1985.tb02082.x","article-title":"Possible Benefits to Veterinary-Medicine of Considering the Dog as a Model for Human Cancer","volume":"26","author":"CG Pierrepoint","year":"1985","journal-title":"J Small Anim Pract"},{"issue":"2","key":"pone.0240807.ref038","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3892\/ol.2016.4718","article-title":"hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study","volume":"12","author":"MV Shepelev","year":"2016","journal-title":"Oncol Lett"},{"issue":"4","key":"pone.0240807.ref039","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/jns.2006.104.4.583","article-title":"The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma","volume":"104","author":"WJ van Houdt","year":"2006","journal-title":"J Neurosurg"},{"issue":"5","key":"pone.0240807.ref040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4161\/cbt.6.5.3957","article-title":"Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy","volume":"6","author":"IV Ulasov","year":"2007","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"pone.0240807.ref041","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.cgt.7700679","article-title":"Transcriptional targeting of tumors with a novel tumor-specific survivin promoter","volume":"11","author":"ZB Zhu","year":"2004","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"pone.0240807.ref042","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bbrc.2007.08.001","article-title":"TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection","volume":"362","author":"X Yao","year":"2007","journal-title":"Biochem Bioph Res Co"},{"issue":"6","key":"pone.0240807.ref043","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1535-7163.687.3.6","article-title":"Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter","volume":"3","author":"YS Haviv","year":"2004","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"pone.0240807.ref044","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/mt.2014.7","article-title":"A pRb-responsive, RGD-modified, and Hyaluronidase-armed Canine Oncolytic Adenovirus for Application in Veterinary Oncology","volume":"22","author":"E Laborda","year":"2014","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0240807.ref045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.imbio.2015.08.007","article-title":"Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology","volume":"221","author":"C Bonnefont-Rebeix","year":"2016","journal-title":"Immunobiology"},{"issue":"12","key":"pone.0240807.ref046","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.leukres.2007.04.003","article-title":"A novel canine lymphoma cell line: A translational and comparative model for lymphoma research","volume":"31","author":"WC Kisseberth","year":"2007","journal-title":"Leukemia Res"},{"issue":"10","key":"pone.0240807.ref047","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11626-007-9060-2","article-title":"Species identification in cell culture: a two-pronged molecular approach","volume":"43","author":"JK Cooper","year":"2007","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"11","key":"pone.0240807.ref048","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/mt.2010.173","article-title":"Minimal RB-responsive E1A Promoter Modification to Attain Potency, Selectivity, and Transgene-arming Capacity in Oncolytic Adenoviruses","volume":"18","author":"JJ Rojas","year":"2010","journal-title":"Mol Ther"},{"issue":"7","key":"pone.0240807.ref049","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.18632\/oncotarget.3217","article-title":"CXCR4 over-expression and survival in cancer: a system review and meta-analysis","volume":"6","author":"H Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"pone.0240807.ref050","first-page":"9","article-title":"Potential Role of CXCR4","author":"F Eckert","year":"2018","journal-title":"Targeting in the Context of Radiotherapy and Immunotherapy of Cancer. Front Immunol"},{"issue":"34","key":"pone.0240807.ref051","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41388-019-0872-9","article-title":"Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players","volume":"38","author":"XT Yuan","year":"2019","journal-title":"Oncogene"},{"issue":"9","key":"pone.0240807.ref052","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.159.9.4322","article-title":"Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry","volume":"159","author":"M Moriuchi","year":"1997","journal-title":"J Immunol"},{"key":"pone.0240807.ref053","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2018.04.003","article-title":"Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect","volume":"11","author":"C Chen","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"issue":"37","key":"pone.0240807.ref054","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/onc.2009.187","article-title":"Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival","volume":"28","author":"YP Sher","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"pone.0240807.ref055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/sj.gt.3302385","article-title":"Evaluation of tumor-specific promoter activities in melanoma","volume":"12","author":"B Lu","year":"2005","journal-title":"Gene Ther"},{"issue":"2","key":"pone.0240807.ref056","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3892\/or.2017.5710","article-title":"Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements","volume":"38","author":"M Sakaguchi","year":"2017","journal-title":"Oncol Rep"},{"issue":"1","key":"pone.0240807.ref057","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.gt.3301619","article-title":"hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity","volume":"9","author":"J Gu","year":"2002","journal-title":"Gene Ther"},{"issue":"1","key":"pone.0240807.ref058","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2478\/s11658-008-0034-5","article-title":"Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells","volume":"14","author":"K Konopka","year":"2009","journal-title":"Cell Mol Biol Lett"},{"issue":"5","key":"pone.0240807.ref059","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/10425170500213696","article-title":"Expression of survivin mRNA in dog tumors","volume":"16","author":"T Uchide","year":"2005","journal-title":"DNA Sequence"},{"issue":"19","key":"pone.0240807.ref060","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1182\/blood-2008-10-185827","article-title":"Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting","volume":"113","author":"AV Kurtova","year":"2009","journal-title":"Blood"},{"issue":"3","key":"pone.0240807.ref061","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.4446","article-title":"CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival","volume":"235","author":"MJ Moreno","year":"2015","journal-title":"J Pathol"},{"issue":"5","key":"pone.0240807.ref062","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ccr.2004.09.027","article-title":"Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis","volume":"6","author":"YM Li","year":"2004","journal-title":"Cancer Cell"},{"key":"pone.0240807.ref063","first-page":"4953","article-title":"CXCR4 in breast cancer: oncogenic role and therapeutic targeting","volume":"9","author":"C Xu","year":"2015","journal-title":"Drug Des Dev Ther"},{"issue":"6","key":"pone.0240807.ref064","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4049\/jimmunol.1402610","article-title":"Bortezomib Inhibits Expression of TGF-beta 1, IL-10, and CXCR4, Resulting in Decreased Survival and Migration of Cutaneous T Cell Lymphoma Cells","volume":"194","author":"TP Chang","year":"2015","journal-title":"J Immunol"},{"issue":"3","key":"pone.0240807.ref065","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1309\/RF4PVCEGGN2XAF86","article-title":"CXCR4\/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1-Th2+immunophenotype","volume":"119","author":"AP Weng","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"pone.0240807.ref066","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.gt.3303105","article-title":"Bidirectional promoter interference between two widely used internal heterologous promoters in a late-generation lentiviral construct","volume":"15","author":"JA Curtin","year":"2008","journal-title":"Gene Ther"},{"key":"pone.0240807.ref067","first-page":"8","article-title":"Viral vectors based on bidirectional cell-specific mammalian promoters and transcriptional amplification strategy for use in vitro and in vivo","author":"B Liu","year":"2008","journal-title":"Bmc Biotechnol"},{"issue":"6","key":"pone.0240807.ref068","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tig.2005.04.009","article-title":"Transcriptional interference\u2014a crash course","volume":"21","author":"KE Shearwin","year":"2005","journal-title":"Trends Genet"},{"issue":"3","key":"pone.0240807.ref069","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0092-8674(82)90456-1","article-title":"Promoter occlusion: transcription through a promoter may inhibit its activity","volume":"29","author":"S Adhya","year":"1982","journal-title":"Cell"},{"issue":"5","key":"pone.0240807.ref070","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.molcel.2004.05.010","article-title":"Transcriptional interference between convergent promoters caused by elongation over the promoter","volume":"14","author":"BP Callen","year":"2004","journal-title":"Mol Cell"},{"issue":"7","key":"pone.0240807.ref071","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jgm.2882","article-title":"Cancer-specific promoters for expression-targeted gene therapy: ran, brms1 and mcm5","volume":"18","author":"X Chen","year":"2016","journal-title":"J Gene Med"},{"issue":"7","key":"pone.0240807.ref072","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1101\/gr.100370.109","article-title":"Sequence features that drive human promoter function and tissue specificity","volume":"20","author":"JM Landolin","year":"2010","journal-title":"Genome Res"},{"issue":"6","key":"pone.0240807.ref073","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","article-title":"MicroRNA and cancer","volume":"6","author":"MD Jansson","year":"2012","journal-title":"Mol Oncol"},{"issue":"24","key":"pone.0240807.ref074","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/sj.onc.1204322","article-title":"Chromatin remodeling: why it is important in cancer","volume":"20","author":"AP Wolffe","year":"2001","journal-title":"Oncogene"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T22:12:20Z","timestamp":1697062340000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0240807"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0240807","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,11,9]]}}}